- Home
- GLRE vs ZBIO Comparison
GLRE vs ZBIO Comparison
Compare GLRE & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- ZBIO
- Stock Information
- Founded
- GLRE 2004
- ZBIO 2019
- Country
- GLRE Cayman Islands
- ZBIO United States
- Employees
- GLRE N/A
- ZBIO N/A
- Industry
- GLRE Property-Casualty Insurers
- ZBIO
- Sector
- GLRE Finance
- ZBIO
- Exchange
- GLRE Nasdaq
- ZBIO NYSE
- Market Cap
- GLRE 466.5M
- ZBIO 389.2M
- IPO Year
- GLRE 2007
- ZBIO 2024
- Fundamental
- Price
- GLRE $14.15
- ZBIO $10.22
- Analyst Decision
- GLRE
- ZBIO Strong Buy
- Analyst Count
- GLRE 0
- ZBIO 7
- Target Price
- GLRE N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- GLRE 166.6K
- ZBIO 217.9K
- Earning Date
- GLRE 08-05-2025
- ZBIO 08-16-2025
- Dividend Yield
- GLRE N/A
- ZBIO N/A
- EPS Growth
- GLRE N/A
- ZBIO N/A
- EPS
- GLRE 1.32
- ZBIO N/A
- Revenue
- GLRE $717,617,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- GLRE N/A
- ZBIO $206.00
- Revenue Next Year
- GLRE N/A
- ZBIO $41.92
- P/E Ratio
- GLRE $10.91
- ZBIO N/A
- Revenue Growth
- GLRE 2.79
- ZBIO N/A
- 52 Week Low
- GLRE $11.95
- ZBIO $5.83
- 52 Week High
- GLRE $15.82
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- GLRE 45.76
- ZBIO N/A
- Support Level
- GLRE $14.26
- ZBIO N/A
- Resistance Level
- GLRE $14.56
- ZBIO N/A
- Average True Range (ATR)
- GLRE 0.30
- ZBIO 0.00
- MACD
- GLRE -0.08
- ZBIO 0.00
- Stochastic Oscillator
- GLRE 9.28
- ZBIO 0.00
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.